To evaluate the efficacy and safety of intravenous zoledronate in treating bone-associated Langerhans cell histiocytosis in children.
Key Findings:
100% of symptomatic patients experienced pain improvement with a median time to improvement of 18 days post-infusion.
Among 8 patients with imaging follow-up, 2 exhibited complete radiographic resolution and 6 showed improvement.
The treatment was well tolerated with transient fever in 4 patients and no significant adverse effects reported.
Interpretation:
Intravenous zoledronate appears to be an effective and well-tolerated treatment option for children with bone-associated LCH, providing rapid pain relief and radiologic improvement.
Limitations:
Small sample size of only eight patients.
Retrospective nature of the study limits the strength of conclusions.
Conclusion:
Zoledronate is a promising adjunctive therapy for managing bone pain in pediatric LCH, warranting further investigation in larger studies.
